Praluent bags EC approval to reduce risk of CV events in patients with ASCD
Regeneron Pharmaceuticals and Sanofi have secured approval for Praluent (alirocumab) for a new indication from the European Commission (EC), which
Continue readingCoverage of Global Pharma Industry News
Regeneron Pharmaceuticals and Sanofi have secured approval for Praluent (alirocumab) for a new indication from the European Commission (EC), which
Continue readingDupixent FDA approval : Dupixent (dupilumab), an eczema drug the co-developed by Sanofi and Regeneron Pharmaceuticals, has been approved by the
Continue readingThe US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) by Regeneron Pharmaceuticals for EYLEA
Continue readingTeva Pharmaceutical Industries and Regeneron Pharmaceuticals said that a phase 3 study evaluating nerve growth factor (NGF) antibody fasinumab in
Continue readingDupixent (dupilumab), the co-developed eczema injection from pharma giants Sanofi and Regeneron Pharmaceuticals, has got the US FDA approval for
Continue readingAtopic dermatitis clinical trial : The jointly developed eczema drug, Dupixent (dupilumab) from Sanofi and Regeneron Pharmaceuticals has met the
Continue reading